Title: Monitoring of minimal residual disease (MRD) and evolution of subclonal architecture during therapy for multiple myeloma (MM) by highly sensitive digital droplet PCR (ddPCR)

Funder
Celgene International II Sarl

Principal Investigator

Project Details
Net value award figure for Cardiff University: £383,334.00
Start date: 21/12/2017
End date: 20/12/2019

Last updated on 2020-03-08 at 06:02